As ibrutinib was effective in disease models that did not depend on B cell antibody production, Chang et al. found that the BTK inhibitor targeted not only B lymphocytes but also mast cells and monocytes, which are critical BTK-expressing effector cells in arthritis and allergy [77]. Here, BTK is linked to arthritic joint disease.